The selective metabotropic glutamate receptor 5 antagonist mavoglurant (AFQ056) reduces the incidence of reflux episodes in dogs and patients with moderate to severe gastroesophageal reflux disease.

M-L Rouzade-DominguezN PezousO J DavidR TutuianS Bruley des VarannesJ TackP MalfertheinerH-D AllescherMike UferA Rühl

Published in: Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society (2017)

These data suggest a potential clinical benefit of mGluR5 antagonists such as mavoglurant in patients with GERD, particularly in those with persisting symptoms despite treatment with proton pump inhibitors.

Keyphrases

gastroesophageal reflux disease
risk factors
high intensity
early onset
sleep quality
machine learning
risk assessment
combination therapy
depressive symptoms
deep learning